9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

Condition Cervical Cancer|Fallopian Tube Cancer|Head and Neck Cancer|Lung Cancer|Malignant Mesothelioma|Ovarian Cancer|Pancreatic Cancer|Primary Peritoneal Cavity Cancer Estimated Enrollment: null Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CDR0000316451|NCI-03-C-0243|NCI-6221|NCI-SS1PE-002 Study First Received: August 6, 2003 Last Updated: April 29, 2015 Estimated Primary Completion Date: null Primary Outcome Measures: Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00066651...

Continue reading

Immunotoxin Therapy in Treating Patients With Advanced Cancer

Condition Cervical Cancer|Fallopian Tube Cancer|Head and Neck Cancer|Lung Cancer|Malignant Mesothelioma|Ovarian Cancer|Pancreatic Cancer|Primary Peritoneal Cavity Cancer Estimated Enrollment: null Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CDR0000068351|NCI-01-C-0011|NCI-6249 Study First Received: December 6, 2000 Last Updated: April 29, 2015 Estimated Primary Completion Date: null Primary Outcome Measures: Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00006981...

Continue reading

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

Condition Adrenocortical Carcinoma|Brain and Central Nervous System Tumors|Head and Neck Cancer|Liver Cancer|Malignant Mesothelioma|Pheochromocytoma|Sarcoma Estimated Enrollment: 30 Age Group: up to 65 Years   (Child, Adult) Gender: All Study Type: Interventional Study Design Allocation: Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CAN-OTT-9401|CDR0000063892|NCI-V94-0566 Study First Received: November 1, 1999 Last Updated: July 9, 2013 Estimated Primary Completion Date: null Primary Outcome Measures: Sponsors and Collaborators: Ottawa Regional Cancer Centre|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00002608...

Continue reading

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

Condition Breast Cancer|Colorectal Cancer|Kidney Cancer|Lung Cancer|Malignant Mesothelioma|Pancreatic Cancer Estimated Enrollment: 40 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Primary Purpose: Treatment Study ID Numbers: SVMC-ONC-222|CDR0000076913|NCI-V91-0075 Study First Received: November 1, 1999 Last Updated: July 9, 2013 Estimated Primary Completion Date: December 2007 Primary Outcome Measures: Clinical response (patients with evaluable disease)|Duration of response (patients with evaluable disease)|Survival (patients with evaluable disease)|Time to recurrence (patients without evaluable disease)|Survival (patients without evaluable disease) Sponsors and Collaborators: St. Vincent Medical Center - Los Angeles|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00002475...

Continue reading

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Condition Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Mesothelioma|Pancreatic Cancer|Prostate Cancer|Sarcoma Estimated Enrollment: 16 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 2007LS086|0712M22703 Study First Received: June 20, 2008 Last Updated: November 6, 2012 Estimated Primary Completion Date: September 2010 Primary Outcome Measures: Maximum tolerated dose of sorafenib tosylate|Disease Response|Maximum, Minimum and AUC Concentrations of Sorafenib Sponsors and Collaborators: Masonic Cancer Center, University of Minnesota Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00703638...

Continue reading

Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Condition Advanced Malignant Mesothelioma|Carcinoma of the Appendix|Ovarian Sarcoma|Ovarian Stromal Cancer|Pseudomyxoma Peritonei|Recurrent Colon Cancer|Recurrent Malignant Mesothelioma|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Stage III Colon Cancer|Stage III Ovarian Epithelial Cancer|Stage III Ovarian Germ Cell Tumor|Stage IV Colon Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Unspecified Childhood Solid Tumor, Protocol Specific Estimated Enrollment: 10 Age Group: Child, Adult, Senior Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care Study ID Numbers: CCCWFU 97110|NCI-2010-00980 Study First Received: May 13, 2010 Last Updated: January 17, 2017 Estimated Primary Completion Date: April 2011 Primary Outcome Measures: Assess feasibility of instituting an orientation program, brief follow up...

Continue reading

Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer

Condition Cancer Estimated Enrollment: 42 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 05-002|12,158 Study First Received: September 16, 2005 Last Updated: January 15, 2016 Estimated Primary Completion Date: October 2013 Primary Outcome Measures: Time-to-progression (TTP)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Overall Survival (OS) Sponsors and Collaborators: University of Pittsburgh|Eli Lilly and Company|Genentech, Inc. Result Received: January 15, 2016 Website Link: https://ClinicalTrials.gov/show/NCT00222729...

Continue reading

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

Condition Cancer Estimated Enrollment: 34 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 114746 Study First Received: September 5, 2013 Last Updated: January 16, 2017 Estimated Primary Completion Date: June 2016 Primary Outcome Measures: Part 1: Safety assessment as assessed by adverse events (AEs) and serious adverse events (SAEs)|Part 1: Safety assessment as assessed by 12-lead electrocardiogram (ECG)|Part 1: Safety assessment as assessed by vital signs|Part 1: Safety assessment as assessed by change from baseline in laboratory values|Part 1: Safety assessment as assessed by echocardiogram|Part 1: Safety assessment as assessed...

Continue reading

Thrombin Generation and Platelet Activation in CRS/HIPEC

Condition Mesothelioma; Peritoneum|Pseudomyxoma Peritonei|Peritoneal Carcinomatosis Estimated Enrollment: 27 Age Group: up to 80 Years   (Child, Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Prospective Study ID Numbers: B37120154199 Study First Received: January 12, 2017 Last Updated: January 24, 2017 Estimated Primary Completion Date: July 2016 Primary Outcome Measures: Blood loss|Red blood cell count|White blood cell count|Platelet count|Fibrinogen levels|Prothrombin Time (PT)|Activated Partial Thromboplastin Time (aPTT)|Endogenous Thrombin Potential (Thrombin generation assay (CAT))|Lag Time (Thrombin generation assay (CAT))|Time-to-Thrombin Peak (Thrombin generation assay (CAT))|Thrombin Peak (TP) (Thrombin generation assay (CAT))|P-selectin expression (Platelet activation test (PACT))|αIIbβ3 activation (Platelet activation test (PACT))|A5 EXTEM (Rotational thromboelastometry (ROTEM))|A5 FIBTEM (Rotational thromboelastometry (ROTEM))|A5 HEPTEM...

Continue reading

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

Condition Lung Cancer|Malignant Mesothelioma|Metastatic Cancer|Thymoma and Thymic Carcinoma Estimated Enrollment: 30 Age Group: Child, Adult, Senior Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CDR0000068889|P30CA016042|UCLA-9908024|NCI-G01-2011 Study First Received: September 13, 2001 Last Updated: October 28, 2015 Estimated Primary Completion Date: December 2006 Primary Outcome Measures: Sponsors and Collaborators: Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00024076...

Continue reading